Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for
harnessing the potential of a patient's own immune system to eliminate tumor cells in …

Cancer immunotherapy attempts to harness the power and specificity of the immune system
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

Dendritic cells (DCs) are considered a very promising arm to activate the immune system in
immunotherapeutic strategies against cancer. DCs are the most powerful antigen-presenting …

Toll-like receptors (TLRs) are the basic signaling receptors of the innate immune system.
They are activated by molecules associated with pathogens or injured host cells and tissue …

Dendritic cells (DCs) are considered as professional antigen presenting cells (APCs),
containing a variety of subsets, that can be resident in organs or migrating among the …

Adoptive transfer of dendritic cells (DCs) transfected with in vitro–transcribed, RNA-
encoding, tumor-associated antigens has recently entered clinical testing as a promising …

RNA vaccines traditionally consist of messenger RNA synthesized by in vitro transcription
using a bacteriophage RNA polymerase and template DNA that encodes the antigen (s) of …

The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses
has stimulated research on harnessing DCs to create more effective vaccines. Early clinical …

In mice, injection of messenger RNA (mRNA) coding for tumor-associated antigens can
induce antitumor immune responses and therefore offers a broadly applicable …